ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 861

Ultraviolet B Generates Type 1 Interferon and Induces Autoantibody-Mediated Disease in a Mouse Model of Cutaneous Lupus

Clayton Sontheimer1 and Keith B. Elkon2, 1Pediatric Rheumatology, University of Washington, Seattle, WA, 2Division of Rheumatology, University of Washington, Seattle, WA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: autoantibodies, cutaneous lupus, interferons, mouse model and skin

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose

Photosensitivity is a common symptom in patients with systemic lupus erythematosus (SLE) and lupus skin lesions often contain plasmacytoid dendritic cells (pDC). The mechanisms linking ultraviolet (UV) light to inflammation and cutaneous flares is not  well understood.  While in vitro experiments have suggested that UV-induced apoptosis exposes lupus-specific nuclear antigens and immune complex mediated inflammation, this has not been shown in vivo.  Here, we asked whether, and under what conditions, UVB-induced inflammation could induce Type I interferon (IFN-I) and the roles of pDCs and also autoantibodies in cutaneous lupus.

Methods

Shaved C57BL/6 (B6), IFNAR KO, BDCA2 DTR, and huFcgR2a transgenic mice were irradiated with narrowband UVB at 100 mJ/cm2/day for 5 consecutive days.  To induce interface dermatitis, shaved and depilated mice were subject  to 15 strokes of tape stripping using medical tape (3M). Serial punch biopsies (6 mm) were obtained at 3, 24, and 72 hrs following UVB exposure or tape stripping. PDCs were detected in enzyme digested skin samples by flow cytometry (CD45+, Ly6C+, PDCA1+, CD11c+, Siglec H+). Skin samples were examined for mRNA expression by QPCR of pro-inflammatory cytokines and Interferon Stimulated Genes (ISG). mRNA fold change was calculated by comparison with  non-irradiated control mice. In experiments with huFcgR2a Tg mice, mice were irradiated as above but injected i.p. at the time of the final UVB exposure with purified immunoglobulin pooled from human lupus patients and the skin was examined by immunofluorescence for the presence of human IgG.

Results

Whereas tape stripping induced a robust ISG response associated with the presence of pDC in the skin, repeated UVB exposure induced a more modest IFN-I skin response with bimodal peaks at 3 and 72 hrs when compared to control mice (p<0.05, n=20).  UVB-irradiated IFNAR KO mice had increased levels of pro-inflammatory cytokines TNFα and IL-6 at (p<0.01 at 3 and 24 hr time points, n=12-13) and had increased levels of inflammation by visual scoring suggesting a protective role for IFN-I. Interestingly, pDCs did not appear to be the source of IFN following UVB as pDC-depleted BDCA2 DTR mice maintained moderate expression of ISGs.  Immunoglobulin from human lupus patients, but not IVIG, localized to the skin at the dermal/epidermal junction following UVB of FcgR2A transgenic and wild-type mice, but FcgR2a signaling was required for cellular uptake and enhanced Type 1 IFN signaling (p<0.05, n=5-9).

Conclusion

In the normal host, repeated doses of UVB induce a protective, pDC-independent Type1 IFN response in the skin that attenuates pro-inflammatory signals and limits tissue damage. In contrast, in situations associated with the presence of autoantibodies as occurs in lupus, the antibodies bind to UVB-exposed antigen, deposit in the skin and require Fcgr2a-mediated uptake to produce enhanced expression of IFN-I.  This novel FcgR2a mouse model of cutaneous lupus establishes the role of UVB in exposing otherwise sequestered nuclear antigens and in facilitating immune-complex mediated skin disease in lupus.


Disclosure:

C. Sontheimer,
None;

K. B. Elkon,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ultraviolet-b-generates-type-1-interferon-and-induces-autoantibody-mediated-disease-in-a-mouse-model-of-cutaneous-lupus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology